

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

INSIDE INFORMATION UPDATE ON TENDER REGARDING PROCUREMENT OF BROMHEXINE HYDROCHLORIDE INJECTION

This announcement is made by SSY Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap 571 of the laws of Hong Kong).

Reference is made to the announcement of the Company dated 14 August 2024 (the “**Announcement**”) in relation to the lowered credit rating in respect of Shijiazhuang No. 4 or its produced Bromhexine Hydrochloride Injection. Capitalised terms used in this announcement shall have the same meaning as those defined in the Announcement, unless the context requires otherwise.

Further to the Notices, on 21 August 2024 (after trading hours), the Company was aware of a public statement (the “**Public Statement**”) published by the National Medicine Joint Procurement Office* (國家組織藥品聯合採購辦公室). It is stated in the Public Statement that Shijiazhuang No. 4 was regarded as in breach of an undertaking in the tender submission document and in breach of the relevant tender provisions of the National Centralized Medicine Procurement Document (GY-YD2022-1)* (全國藥品集中採購文件 (GY-YD2022-1)) in respect of the Bromhexine Hydrochloride Injection tender (the “**Tender**”) under the seventh batch of the National Centralized Procurement. The Public Statement confirms that (i) Shijiazhuang No. 4’s winning bid in the Tender has been cancelled; and (ii) Shijiazhuang No. 4 has been put onto the “List of Contravention of Provision” and, in view of its active cooperation, will be suspended for eligibility for participating in the National Centralized Procurement for a period of six months from 21 August 2024 to 20 February 2025 (the “**Term**”).

The Public Statement does not affect tenders other than the Tender regarding Bromhexine Hydrochloride Injection won by Shijiazhuang No. 4 under the seventh batch and other batches of the National Centralized Procurement outside the Term, or the Group's sales of products by channels other than centralized procurements. Accordingly, only a very small portion of the Group's overall sales regarding the Term would be affected and, during the Term, the Group would allocate resources to expand its sales of products, including its Bromhexine Hydrochloride Injection, by channels other than centralized procurements. As such, as at the date of this announcement, the Company considers that the Public Statement has no material adverse effect on the operations or financial position of the Group as a whole.

The Group is committed to the development of sustainable operations through the maintenance of good corporate governance and an effective risk management framework. The Company will continue to strengthen its compliance standards, including but not limited to monitoring and control of its operational practices under its established anti-corruption policies, so as to ensure that the operations of the Group will be guided by the principles of fairness and integrity.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 21 August 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.

** For identification purposes only*